(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 September 2018 (27.09.2018)

WIPO | PCT

(10) International Publication Number
WO 2018/174149 A1

(51) International Patent Classification:
A61K 31/439 (2006.01) *A61P 27/10* (2006.01)

(21) International Application Number:
PCT/JP2018/011361

(22) International Filing Date:
22 March 2018 (22.03.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10201702378S 23 March 2017 (23.03.2017) SG

(71) Applicants: **SINGAPORE HEALTH SERVICES PTE LTD** [SG/SG]; 31 Third Hospital Avenue, #03-03 Bowyer Block C, Singapore, 168753 (SG). **SANTEN PHARMACEUTICAL CO., LTD.** [JP/JP]; 9-19, Shimoshinjo 3-chome, Higashiyodogawa-ku, Osaka-shi, Osaka, 5338651 (JP).

(72) Inventors: **TAN, Donald**; c/o Singapore Eye Research Institute, 11 Third Hospital Ave, Singapore, 168751 (SG). **BEUERMAN, Roger**; c/o Singapore Eye Research Institute, 11 Third Hospital Ave, Singapore, 168751 (SG). **SAW, Seang-Mei**; c/o Singapore Eye Research Institute, 11 Third Hospital Ave, Singapore, 168751 (SG). **UPADHYAY, Aradhana**; 283, Bedok South Avenue 3, unit 14-43, Singapore, 465460 (SG). **KATO, Masatomo**; c/o SANTEN PHARMACEUTICAL CO., LTD., 8916-16, Takayama-cho, Ikoma-shi, Nara, 6300101 (JP). **INABA, Takaaki**; c/o SANTEN PHARMACEUTICAL CO., LTD., 8916-16, Takayama-cho, Ikoma-shi, Nara, 6300101 (JP).

(74) Agent: **SAMEJIMA, Mutsumi** et al.; AOYAMA & PARTNERS, Umeda Hankyu Bldg. Office Tower, 8-1, Kakuda-cho, Kita-ku, Osaka-shi, Osaka, 5300017 (JP).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2018/174149 A1

(54) Title: AGENT FOR PREVENTING MYOPIA, TREATING MYOPIA, AND/OR PREVENTING MYOPIA PROGRESSION COMPRISING TIOTROPIUM AS ACTIVE INGREDIENT

(57) Abstract: The present invention relates to an agent for preventing myopia, treating myopia, and/or preventing myopia progression, comprising tiotropium as an active ingredient.